Obiteljska hipokalciurična hiperkalcemija i receptor osjetljiv na kalcij by Monija Mrgan et al.
220 Acta Clin Croat,  Vol. 53,   No. 2,  2014
Acta Clin Croat 2014; 53:220-225 Review
FAmiliAl hypoCAlCiuRiC hypeRCAlCemiA And 
CAlCium sensing ReCeptoR
monija mrgan1, sanne nielsen1 and Kim Brixen2
1sydvestjysk sygehus, esbjerg; 2odense universitetshospital, odense, denmark
summARy –Familial hypocalciuric hypercalcemia (Fhh) is a lifelong, benign autosomal do-
minant disease characterized by hypercalcemia, normal to increased parathyroid hormone level, and 
a relatively low renal calcium excretion. inactivation of the calcium-sensing receptor in heterozy-
gous patients results in Fhh, while in homozygous patients as well as in compound heterozygous 
or dominant negative heterozygous patients, it may result in neonatal severe hyperparathyroidism 
(nshpt). parathyroid surgery is not indicated in Fhh and does not lower plasma calcium unless 
total parathyroidectomy is performed, in which case hypocalcemia ensues. There is currently no 
definitive medical treatment available, although pamidronate can be used to stabilize these patients 
before parathyroidectomy. some nshpt patients are asymptomatic subsequently in their lives. in 
this paper, clinical characteristics of this relatively rare disorder are presented.
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The Role of Calcium in the Human Body
many physiological processes in the human body 
use either intracellular or extracellular Ca2+. intracel-
lular Ca2+ exists in the cytosol of all cell types, work-
ing as a second messenger and enzyme cofactor. it 
coordinates and controls, i.e. modulates, various cell 
functions including muscle contractions, hormone se-
cretion, glycogen metabolism, cell differentiation and 
proliferation, cell motility, and nerve cell function1.
under normal conditions, the intracellular concen-
tration of Ca2+ is 100 nmol/l, i.e. much less than in the 
extracellular phase. The concentration of intracellular 
Ca2+ fluctuates by about 1 mmol/l upon cell activation, 
either due to the release of Ca2+ from intracellular stores 
or because of the increased calcium influx, but also due 
to the calcium-induced calcium release from the sar-
coplasmic reticulum. The concentration of extracellular 
Ca2+ (i.e. blood levels) remains virtually constant due to 
the sensitive homeostatic mechanism1.
under normal conditions, the plasma level of 
calcium is highly regulated through the calciotropic 
hormones, i.e. parathyroid hormone (pth), 1,25-di-
hydroxy-vitamin d, and to a lesser extent calcitonin. 
pth is the most important and fastest regulator of 
the calcium level in serum. The cells of the parathy-
roid glands are Ca2+ sensitive and respond to even 
small and transient changes of the extracellular Ca2+ 
concentration. pth increases the release of Ca2+ 
from the bones, enhances distal tubular Ca2+ reab-
sorption of the kidneys, and simultaneously reduces 
phosphate reabsorption1. it is worth noticing that in-
creased [Ca2+]i inhibits pth secretion in contrast to 
most other signaling pathways where increased [Ca2+]i 
stimulates secretion of the relevant hormone.
The Role of the Calcium-Sensing Receptor in 
Calcium Homeostasis of Humans
For a long time, one has expected the existence 
of a receptor closely regulating the level of calcium 
in humans. The calcium-sensing receptor (CasR) 
in humans was detected by the expression cloning 
technique by Brown et al. in 19932. There has been 
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an explosion of interest in the CasR since it was first 
cloned. The CasR is a glucoprotein belonging to the 
Family C ii of the superfamily of g-protein coupled 
receptors. members of the Family C ii receptors are 
expressed both centrally and in peripheral tissues. 
All these receptors are, in general, composed of 4 
main protein domains:
1) an atypically large hydrophobic n-terminal extra-
cellular, nutrient binding, Venus Flytrap (VFt) 
domain;
2) cysteine-rich domain that couples nutrient bind-
ing to receptor activation;
3) 7-transmembrane domain (tmd), which is in-
volved in the process of ligand-induced signaling 
and g-protein activation; and
4) intracellular C-terminal signaling domain (iCd), 
which is required for the activation of intracellular 
signaling pathways3,4.
Recent studies have demonstrated that the CasR 
forms disulfide-linked dimers5. CasR couples to 
phosphatidylinositol (pi) specific phospholipase C 
and induces mobilization of intracellular Ca2+. This 
explains why elevated concentrations of extracellular 
Ca2+ and mg2+ rapidly induce intracellular Ca2+ mo-
bilization and inositol phosphate turnover in parathy-
roid cells via g-protein dependent activation of pi-
specific phospholipase C. Ca2+, and to a lesser degree 
mg2+, is bound to the extracellular n-terminal part of 
the CasR. Ca2+ is released from the endoplasmic re-
ticulum, and simultaneously the influx of extracellular 
Ca2+ is increased through voltage-independent calci-
um channels. Thus, a cascade of intracellular changes 
is initiated mediating an effect corresponding to the 
recorded level of p-Ca2+3,6 .
CasR is found in the chief cells of the parathy-
roid glands, the C-cells of the thyroid gland, the renal 
cells, the gut and the bones. in the gut, CasR seems 
to be involved in sensing of amino acids, and in the 
bones CasR inhibits the formation and activity of os-
teoclasts and stimulates osteoblasts. The C-cells of the 
thyroid gland increase calcitonin secretion4.
The main function of the CasR is the regulation of 
the synthesis and secretion of pth by the parathyroid 
glands. By means of the CasR, the cells are able to sense 
local changes in the concentration of Ca2+ and thereby 
change their functions. An increase in Ca2+ leads to 
the activation of CasR resulting in a decrease in pth 
secretion. on the other hand, a decrease in the serum 
Ca2+ level inactivates the CasR that evokes an increase 
in pth secretion within few seconds or minutes6.
The concentration of extracellular Ca2+ resulting 
in 50% inhibition of the maximal pth-secretion is 
referred to as the calcium set-point. The calcium set-
point reflects the sensitivity of the CasR to extracel-
lular Ca2+. A large number of mutations in the gene 
coding for the CasR have been demonstrated to affect 
the calcium set-point (see Fig. 1)7.
polymorphisms are common variations of dnA. in 
contrast to a mutation, it is defined as a non-pathogenic 
change, but in some extremely rare cases it can cause 
mild disease. in some cases, polymorphisms might af-
fect the set-point of the receptor, but often to a very 
small degree, and thus discrete or intermittent hyper-
calcemia can be induced. These patients are often iden-
tified in relation to diagnosing hypercalcemia.
in kidneys, CasR is expressed in all nephron seg-
ments (see table 1), with the possible exception of the 
glomeruli, where its presence is debated8.
The functionally important mutations in the CasR 
lead to changes in the calcium homeostasis and to dis-
eases. mutations in the gene coding for the CasR can 
cause disruptions of the calcium homeostasis and even-
tually a disease, since the mutation can either activate or 
inactivate CasR. Activation of the receptor can result 
in autosomal dominant hypocalcemia (see table 1). on 
the other hand, inactivation of the receptor can cause fa-
milial hypocalciuric hypercalcemia (Fhh) in heterozy-
gous patients (see table 1). different mutations cause 
hypercalcemia of various degrees of clinical severity (see 
table 2)9. inactivation of the receptor in homozygous 
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nant negative heterozygous patients, results in neonatal 
severe primary hyperparathyroidism (nshpt)10.
At least 64 inactivating mutations have previously 
been described in the CasR gene. Christensen et al. 
have recently described 22 inactivating mutations, of 
which 19 are novel. A significant phenotype differ-
ence (e.g., difference in the degree of hypercalcemia) 
was detected among individual mutations11.
Familial Hypocalciuric Hypercalcemia
in 1966, Fhh was described for the first time and 
was named familial hpt by Jackson and Boonstra7. 
Table 1. Renal effects of calcium-sensing receptor (CaSR)8
nephron segment effect of CasR
Juxtaglomerular apparatus – CasR activation inhibits renin secretion by reducing cAmp synthesis8
proximal tubule – CasR activation results in an antiphosphaturic effect8
Thick ascending loop of henle 
(tAlh)
– CasR stimulation may have an inhibitory effect on sodium/potassium/chlo-
ride carrier (nKCC2) activity via several mechanisms
– CasR activation diminishes Ca2+ and mg2+
– CasR also inhibits low-conductance potassium channels (RomK) activity 
and sodium-potassium pump activity, and pth-stimulated calcium reab-
sorption in the cortical tAlh8
distal convoluted tubule
– CasR inhibits active calcium reabsorption mediated by the basolateral cal-
cium pump (pmCA) through protein kinase C activation
– CasR also reduces potassium flux through the potassium channels by inter-
acting directly with them. The drop in potassium efflux has a negative effect 
on sodium-potassium pump activity and reduces sodium reabsorption8
Collecting duct
– These cells express water channels of type 2 (AQp-2), but also AQp-3 and 4
– Vasopressin binding to their V2 receptor leads to AQp-2 insertion in the 
luminal membrane and elicits antidiuresis. CasR is expressed on the luminal 
membrane and antagonizes vasopressin activity by altering AQp-2 trafficking, 
thus reducing urine concentration capacity8. This inhibition of maximal urinary 
concentrating capacity may have physiologic relevance as a means of avoiding 
excessive levels of Ca2+ in the distal urinary collecting system that might other-
wise predispose to renal stone formation during times of antidiuresis10
Furthermore, in 1972, the disease was characterized 
and named familial benign hypercalcemia by Foley be-
cause the disease is generally asymptomatic and does 
not require treatment, in contrast to the homozygous 
disease nshpt7,12. Finally, in 1977, the condition was 
termed Fhh by marx et al.13. The cause of the disease 
was first known in 1993, when CasR in humans was 
detected by the expression cloning technique by Brown 
et al.2. Familial hypocalciuric hypercalcemia is an auto-
somal dominant disease with 100% penetrance. since 
the disease is autosomal dominant, half of an offspring 
will statistically inherit the disease, and because of the 
high penetrance, hypercalcemia will be observed in all 
Table 2. Disease related to calcium-sensing receptor (CaSR)9
Activating mutation inactivating mutation
Autosomal dominant hypocalcemia (Adh) Familial hypocalciuric hypercalcemia (Fhh)
idiopathic hypercalciuria (ih) neonatal severe hyperparathyroidism (nshpt)
idiopathic epilepsy (ie) expression in a kindred of Fhh or nshpt affected members (Fhh/nshpt)
Bartter`s syndrome type V Familial isolated hyperparathyroidism (Fihp)
tropical chronic pancreatitis (tCp)
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heterozygous patients with Fhh. hypercalcemia can 
be observed in these patients at all ages, even during 
the first week of their lives13. The prevalence of Fhh 
is approximately 1:10,0007. The gene responsible for 
Fhh was at first mapped to the long arm of chromo-
some 3 (Fhh1). locus on this chromosome has been 
documented to be the gene encoding the CasR. A phe-
notypically similar disorder has been linked to 2 differ-
ent loci (short arm = Fhh2 and long arm = Fhh3) on 
chromosome 19. Fhh3 is also referred to as the okla-
homa variant14. Fhh patients are usually asymptom-
atic, but their biochemical features are very similar to 
primary hyperparathyroidism (phpt), which is why 
these can easily be confused. however, it is important 
to differentiate between Fhh and phpt because the 
prognosis and treatment differ15. phpt is character-
ized by hypercalcemia, hypercalciuria, enlarged para-
thyroid glands and significantly increased concentra-
tion of serum pth. phpt is treated efficiently with 
parathyroidectomy7,16. Fhh is characterized by hy-
percalcemia, relative hypocalciuria and inappropriately 
normal to high levels of pth10. The increased serum 
pth concentration in relation to the patient’s hyper-
calcemia reflects an altered calcium set-point7. Further-
more, Fhh patients are characterized by a moderately 
increased serum magnesium level and normal serum 
phosphate level6. There are significant similarities be-
tween the characteristics of these diseases. 
Christensen et al. used the Receiver operat-
ing Characteristics (RoC) analysis and an overlap 
analysis to demonstrate that the calcium/creatinine 
clearance ratio (CCCR) was marginally better in dif-
ferentiating between Fhh and phpt compared to 
other estimations of renal calcium excretion. CCCR 
is generally less than 0.01 in patients with Fhh and 
higher than 0.02 in patients with phpt. unlike 
phpt, most patients with Fhh do not have osteo-
porosis, renal function deficits, ulcer disease, or in-
creased risk of cardiovascular disease16. in the clinical 
setting, the distinction between Fhh and phpt is 
often based on the CCCR in hypercalcemic patients 
with clinical suspicion of phpt or Fhh. A two-
step diagnostic procedure has been proposed, where 
the first step is based on the CCCR with a cut-off 
at <0.02, and the second step is CasR gene analy-
sis in patients with Fhh or phpt16. Christensen 
et al. demonstrated Fhh patients to have normal 
25-oh-vitamin-d, but increased 1,25-(oh)2-
vitamin-d (compared with population based sex-, 
age- and season-matched normal controls). They 
also concluded that inactivating CasR mutations 
do not cause deleterious effects on bone as evaluated 
by dXA measurements, in spite of increased plasma 
levels of pth and alkaline phosphatase compared to 
normal control11,17.
Familial hypocalciuric hypercalcemia cannot be 
cured and is resistant to partial parathyroidectomy, 
since the condition is due to a general defect in the 
CasR throughout the body and not only localized to 
the parathyroid glands. total parathyroidectomy re-
sults in hypocalcemia7. 
Complications reported by Fhh patients are re-
curring pancreatitis and chondrocalcinosis. in addi-
tion, there is a risk of inappropriate parathyroidec-
tomy. There are uncertainties as to the occurrence of 
osteoporosis, myopathy, nephrolithiasis, diabetes and 
hypertension in Fhh patients. Fhh should be treat-
ed if patients have severe symptoms7. Recent studies 
show that cinacalcet (mimpara®) can restore calcium 
sensitivity of the parathyroid glands and treatment 
with this agent might be useful in preventing compli-
cations of Fhh18.
essentially, the patients’ lists of prescribed drugs 
must be revised since several drugs affect the me-
tabolism of calcium. Fhh patients with osteoporosis 
must take vitamin d supplement, since it has a better 
effect on preventing fractures and preserving muscle 
function than calcium supplementation. A few Fhh 
patients have developed phpt. Thus, annual mea-
surement of serum Ca2+ and pth is recommended7.
moreover, family screening is important in order 
to avoid unnecessary parathyroidectomy in patients 
with asymptomatic hypercalcemia. Furthermore, 
measurement of Ca2+ in family members is indicated 
if differentiation between Fhh and phpt in the 
proband is difficult7.
Conclusion
Although the disease has been known since 
1966, we still know very little about it and further 
research is required. Fhh is easily confused with 
milder cases of the more common phpt, which is 
generally treated by parathyroidectomy. in the case 
of Fhh, parathyroidectomy is not only unnecessary 
224 Acta Clin Croat,  Vol. 53,   No. 2,  2014
monija mrgan et al. Fhh and CasR
but also inappropriate, since it does not cure Fhh-
associated hypercalcemia. it is therefore important to 
identify patients with Fhh to prevent unnecessary 
parathyroidectomy. Recent studies show that cina-
calcet (mimpara®) can restore calcium sensitivity of 
the parathyroid glands and treatment with this agent 
might be useful in preventing complications of Fhh. 
since most cases of Fhh are associated with loss-of-
function mutations in a single gene (CASR), genetic 
testing can assist in the diagnosis of Fhh. genetic 
testing for Fhh-associated mutations in CasR can 
help prevent unnecessary and inappropriate parathy-
roidectomy in patients with Fhh.
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sažetak
oBitelJsKA hipoKAlCiuRičnA hipeRKAlCemiJA i ReCeptoR osJetlJiV nA KAlCiJ
M. Mrgan, S. Nielsen i K. Brixen
obiteljska hipokalciurična hiperkalcemija je relativno čest uzrok asimptomatske hiperkalcemije. obiteljska hipokalci-
urična hiperkalcemija je autosomno dominantni poremećaj obilježen umjerenom hiperkalcemijom i relativnom hipokalci-
urijom. obiteljska hipokalciurična hiperkalcemija nastaje uslijed inaktivirajuće mutacije gena za CasR, receptor osjetljiv 
na kalcij. najčešće ovaj poremećaj ne zahtijeva kirurško liječenje, kako je to slučaj s drugim oblicima primarnog hiperpara-
tireoidizma. pokušaji da se hiperkalcemija liječi lijekovima nisu bili uspješni i nisu snizili razinu kalcija u serumu. studije 
pokazuju da sinakalcet (mimpara®) može zaustaviti nenormalno prepoznavanje serumskog kalcija od strane paratireoidnih 
žlijezda, tako da dođe do normalne sekrecije paratireoidnog hormona. u ovom radu opisane su kliničke manifestacije ove 
relativno rijetke bolesti. 
Ključne riječi: Hiperkalcemija, prirođena; Receptori osjetljivi na kalcij; Hiperkalcemija – farmakoterapija
